Adinolfi LE, Petta S, Fracanzani AL, et al. - Whether a reduction in cardiovascular events (CV) events can be seen with HCV eradication, was determined in this prospective multicentre study including 2,204 HCV patients [48% males, median age 68 (59–74) years and BMI 25.9 (23.1–28)]. Patients who smoked, had diabetes, had cholesterol levels >200 mg/dl were 24.7%, 18%, and 13.2%, respectively. Among participants, 9.1% received statins and 44% had hypertension. Control group included 2,204 patients. A total of 1,668 patients following HCV elimination were followed as a case group. In pretreatment and untreated controls and treated cases, incident CV rates per 100 patient years were estimated to be 1.12, 1.14 and 0.44, respectively, and a decrease of relative risk was observed. Researchers reported a 2.0–3.5 times lower CV risk compared with controls. The annual incidence decrease in CV events was estimated to be 0.68%. An independent link of HCV clearance with CV events reduction was identified. Overall, a reduction in CV events (ischemic heart disease and ischemic cerebral stroke) was brought about by HCV clearance using direct-acting antivirals, affording both clinical and socio-economic benefits.